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Abstract Finding an effective treatment strategy for
rheumatoid arthritis (RA) patients who have not beneﬁted
from previous tumor necrosis factor–a antagonist treatment
is important for minimizing RA disease activity and
improving patient outcomes. The aim of this study was to
comparethesafetyandeffectivenessofetanerceptinpatients
with and without inﬂiximab (IFX) treatment experience.
Patients (n = 7,099) from a large postmarketing observa-
tional study of etanercept use in Japan were divided into 2
cohorts based on previous IFX use (pre-IFX and non-IFX).
Baseline characteristics were assessed in each cohort.
Adverse events (AEs) and European League Against Rheu-
matism (EULAR) responses were monitored every 4 weeks
for 24 weeks. At baseline, pre-IFX patients were younger
and had fewer comorbidities and a shorter RA duration than
non-IFX patients. During the study, pre-IFX patients
receivedconcomitantmethotrexatemoreoftenthannon-IFX
patients. The incidence of AEs and serious AEs were sig-
niﬁcantlylowerinpre-IFXpatients,aswasthepercentageof
patients who discontinued treatment. Both cohorts had sig-
niﬁcant improvement (P\0.001) in EULAR responses at
theendofthetreatmentperiod.Thisstudydemonstratedthat
etanercept was effective and well tolerated in active RA
patients with and without prior IFX treatment.
Keywords Etanercept  Inﬂiximab  Postmarketing
surveillance study  Rheumatoid arthritis  TNF-a
antagonists
Introduction
The goals of managing rheumatoid arthritis (RA) are to
control or prevent damage to the joints, decrease pain, and
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European League against Rheumatism (EULAR; disease
activity score in 28 joints [DAS28] \2.6) is currently a
realistic and achievable goal of RA treatment [2, 3]. There
are various treatment strategies to achieve remission, such
as combination therapy with disease-modifying antirheu-
matic drugs (DMARDs) or therapy with tumor necrosis
factor–a (TNF-a) inhibitors (monotherapy or combination
therapy) [3, 4]. Combination therapy using TNF-a antag-
onists plus traditional DMARDs is a common strategy for
the treatment of RA and improves the clinical outcomes in
patients who previously received monotherapy [5]. In
particular, the combination of TNF-a antagonists and
methotrexate (MTX) results in better clinical and radio-
graphic responses than when either agent is used alone [6,
7].
A relatively recent concern in RA disease management
is the treatment of patients who do not respond to initial
anti–TNF-a therapy. Up to approximately one-third of
patients treated with TNF-a antagonists fail to respond or
develop adverse events (AEs) that lead to treatment dis-
continuation [8–10]. The use of biologics such as rituximab
[11] and abatacept [12] with a different mechanism of
action may be an option for such patients; however, several
studies have shown that patients who do not tolerate or
respond to initial treatment with a TNF-a antagonist can
beneﬁt by switching to a different TNF-a antagonist
(despite the fact that both agents target TNF-a)[ 13–21].
Conclusions regarding the beneﬁt of switching TNF-a
inhibitors from these studies have, however, been limited
by relatively small patient numbers.
The Japanese postmarketing survey for etanercept
(ETN; a fully human soluble TNF receptor fusion protein)
registered all patients treated with ETN in Japan, including
a large number of patients who had switched from inﬂix-
imab (IFX) to ETN therapy. The purpose of this post hoc
analysis of interim data (for the ﬁrst 7,099 patients; anal-
ysis for all 13,894 patients is still ongoing) from the
postmarketing survey is to evaluate the safety and effec-
tiveness of ETN among patients who discontinued IFX
treatment because of a lack of effectiveness or AEs.
Patients and methods
Patients
This study enrolled 13,894 Japanese patients with RA
(aged C 18 years) with and without prior IFX experience
participating in a postmarketing surveillance study of ETN
use between March 2005 and April 2007. This Post-Mar-
keting Surveillance Program was conducted under Phar-
maceutical Affairs Law, which collects data and
information from usage of products within product labeling
under daily clinical practice. Patient eligibility for ETN
treatment was evaluated according to the Japan College of
Rheumatology guidelines [22], and the protocol was
reviewed and approved by the Japanese Ministry of Health,
Labor, and Welfare. ETN was indicated for patients with
active RA despite DMARD treatment for [3 months, C6
tender joints, C6 swollen joints, and erythrocyte sedi-
mentation rate (ESR) C28 mm/h or C-reactive protein
(CRP) C2.0 mg/dL. Patients also had to have a low risk for
opportunistic infections (white blood cell count C4,000/
mm
3, peripheral blood lymphocyte count C1,000/mm
3, and
negative serum b-D-glucan). Contraindications for ETN
treatment included ongoing infection, history of serious
infection in the previous 6 months, history of tuberculosis
infection or Pneumocystis carinii pneumonia, congestive
heart failure, or malignancy or demyelinating disease.
Mandatory chest radiographs and tuberculin tests were
conducted before initiation of treatment.
Study design/assessments
Patients receiving ETN were divided into 2 groups based
on their history of IFX use and were categorized as either
having previous IFX treatment (pre-IFX) or no prior IFX
treatment (non-IFX). Etanercept 10–25 mg was adminis-
tered subcutaneously twice weekly. Patients could self-
inject after receiving appropriate training from healthcare
professionals. Safety and effectiveness data were collected
every 4 weeks for 24 weeks. The primary effectiveness
endpoint was EULAR response.
Statistical analysis
In this post hoc analysis, missing effectiveness data were
accounted for using last-observation-carried-forward
(LOCF) methods, except for baseline values, which were
not carried forward. Fisher’s exact test and t-test were used
to assess differences between pre-IFX patients and non-
IFX patients in baseline characteristics, treatment effec-
tiveness (DAS28 response according to EULAR criteria),
and serious AEs. Continuation rates of etanercept between
the pre-IFX and non-IFX groups were compiled to generate
a Kaplan–Meier plot and were tested using log-rank test.
Furthermore, Cox proportional hazard models were applied
to estimate relative risks and 95% CIs of serious AEs in
relation to pre-IFX treatment, after adjustment for major
confounders including age, sex, Steinbrocker functional
class 4, duration of RA, history of infectious disease, his-
tory of tuberculosis, presence of any comorbidities, and
concomitant DMARD use. Also, multiple logistic regres-
sion models were used to estimate the effect of pre-IFX
treatment on the likelihood of achieving a moderate to
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founders. All statistical analyses were performed using
SAS, version 8.2, software (SAS Institute, Inc., Cary, NC).
Two-sided P values of less than 0.05 were considered to
indicate statistical signiﬁcance.
Results
Patient characteristics
This interim analysis evaluated the safety and effectiveness
of ETN among the ﬁrst 7,099 patients (908 pre-IFX and
6,191 non-IFX patients) out of 13,894 patients enrolled.
Most baseline characteristics differed signiﬁcantly between
pre-IFX and non-IFX patients (Table 1). Patients in the
pre-IFX group tended to be younger than patients in the
non-IFX group (mean age, 54.2 and 58.9 years, respec-
tively, P\0.001) and had a shorter duration of RA (9.0
and 9.9 years, respectively, P\0.001) and fewer comor-
bidities (52.0 and 59.1%, respectively, P\0.001). In the
pre-IFX patients, concomitant DMARD use at the enroll-
ment to the study was higher compared with non-IFX
patients (87.1 and 68.7%, respectively, P\0.001), as was
the concomitant use of MTX (80.9 and 48.6%, respec-
tively, P\0.001).
Treatment rationale and compliance
Within the cohort of pre-IFX patients (n = 908), most
patients (94%, n = 856) switched from IFX to ETN
treatment because of a lack of IFX effectiveness. In cases
in which initial IFX treatment was effective (6%, n = 52),
the majority of patients (73%, n = 38) switched to ETN
because of treatment-related AEs.
Etanercept compliance was monitored in pre- and non-
IFX cohorts for 24 weeks. Pre-IFX group showed
signiﬁcantly higher continuation rate than non-IFX group
(87.9% vs. 82.3%, P\0.001) (Fig. 1). Of the entire study
population, 17.0% (n = 1,208) of patients treated with
ETN discontinued use, and most discontinued because of
AEs (8.6%, n = 608) rather than a loss of effectiveness
(2.6% n = 185). Among the patients who discontinued
treatment because of AEs, pre-IFX patients had a signiﬁ-
cantly lower rate of ETN discontinuation compared with
non-IFX patients (5.0% vs. 9.1%; P\0.001). There was
no statistical difference in discontinuations due to lack of
effectiveness between pre- and non-IFX patients.
Safety
Approximately 34% (n = 2,424) of the patients in this
study reported an AE during the observation period. For
both groups, the most common AE was infection. Overall,
6.4% (n = 452) of patients reported a serious AE during
the study. The incidence of AEs and serious AEs (SAEs)
was signiﬁcantly lower in the pre-IFX group than in the
non-IFX group (P\0.001 and P = 0.004, respectively;
Table 1 Patient characteristics
DAS28 Disease Activity Score
including 28-joint count;
DMARDs disease-modifying
antirheumatic drugs; IFX
inﬂiximab; MTX methotrexate;
ns not signiﬁcant; RA
rheumatoid arthritis
* n = 501 for patients
switching from IFX; n = 4,142
for patients not switching from
IFX
Pre-IFX patients Non-IFX patients P value
Number of patients 908 6,191
Sex, n (%)
Men 186 (20.5) 1,160 (18.7) ns
Women 722 (79.5) 5,031 (81.3) ns
Mean age ± SD, years 54.2 ± 13.2 58.9 ± 12.7 \0.001
Mean body weight ± SD, kg 54.2 ± 9.8 53.1 ± 10.2 0.018
Presence of any past history, n (%) 224 (24.7) 1,855 (30.0) \0.001
Comorbidities present, n (%) 472 (52.0) 3,661 (59.1) \0.001
Mean duration of RA, years 9.0 9.9 \0.001
Previous steroid use, n (%) 824 (90.8) 5,248 (84.8) \0.001
Mean DAS28 ± SD* 6.1 ± 1.2 6.0 ± 1.2 ns
Concomitant use of DMARDs, % 87.1 68.7 \0.001
Concomitant use of MTX, n (%) 80.9 48.6 \0.001
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Fig. 1 Kaplan–Meier analysis for continuation rates of etanercept
between the pre-IFX and non-IFX groups. IFX = inﬂiximab.
P\0.001 for pre-IFX vs. non-IFX (log-rank test)
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123Table 2). In patients who received MTX concomitant with
ETN, there was no increase in the risk of SAEs relative to
ETN monotherapy (Fig. 2). The incidence of SAEs in non-
IFX patients treated with doses of MTX C 10 mg/wk was
signiﬁcantly lower than in patients treated with ETN alone
(P = 0.019). Compared with the non-IFX group, pre-IFX
patients had a non-signiﬁcantly lower risk for SAE
occurrence (multivariate hazard ratio, 0.75; 95% CI,
0.54–1.06; P = 0.098).
Effectiveness
Etanercept was effective, as measured by EULAR response
through the treatment period, in both pre-IFX and non-IFX
patients. The majority of pre-IFX patients ([80%)
responded to ETN treatment (Fig. 3). According to the
EULAR response criteria of no response, moderate
response, and good response, the number of good responses
increased signiﬁcantly (P\0.05) at week 8 and beyond in
the non-IFX group and at week 12 and beyond in the pre-
IFX group (P\0.05). Remission was achieved in 14.4%
of the patients in the pre-IFX group after switching to ETN
(vs. 16.6% of the patients in the non-IFX group). There was
no signiﬁcant difference in achieving a good or moderate
EULAR response between the non-IFX and pre-IFX
groups (multivariate odds ratio, 0.93; 95% CI, 0.70–1.25;
P = 0.64).
Discussion
In clinical practice, it is important to consider the beneﬁt of
prescribing a second TNF-a antagonist if an initial anti–
TNF-a treatment has not been effective. Indeed, multiple
TNF-a inhibitors are currently in clinical use, and although
all TNF-a inhibitors have the same target [23], each drug is
unique in its mechanism of action and pharmacologic
properties (Table 3)[ 24–26], which can result in variations
in clinical outcomes. In this study of 7,099 Japanese
patients with RA, the largest study to date to evaluate the
beneﬁt of TNF-a switching, ETN was effective in patients
with a history of prior IFX use as well as in those who were
naive to IFX therapy. In the case of patients for whom prior
IFX therapy had failed and who were subsequently treated
with ETN, [80% were able to attain a moderate to good
EULAR response by the end of the study period, similar to
Table 2 Incidence of adverse
events
IFX inﬂiximab; ns not
signiﬁcant
Adverse event, n (%) Pre-IFX patients
(n = 908)
Non-IFX patients
(n = 6,191)
Total
(n = 7,099)
P value
Any adverse event 265 (29.2) 2,159 (34.9) 2,424 (34.1) \0.001
Serious adverse events 42 (4.6) 500 (8.1) 542 (7.6) \0.001
Death 2 (0.2) 31 (0.5) 33 (0.5) ns
Malignancy 1 (0.1) 17 (0.3) 18 (0.3) ns
Serious infection 23 (2.5) 202 (3.3) 225 (3.2) ns
Non-serious infection 55 (6.1)) 473 (7.6) 528 (7.4) ns
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Fig. 2 Incidence rate of serious
adverse events by dose of MTX.
IFX inﬂiximab; MTX
methotrexate. *P\0.05 for all
doses versus 0 mg MTX
(Fisher’s exact test). Values in
parentheses indicate number of
subjects per group
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123the effectiveness observed in IFX-naive patients treated
with ETN. Moreover, ETN was able to induce remission in
a subset of patients for whom prior IFX therapy had failed.
Importantly, the majority (810 of 860; 94%) of pre-IFX
patients in this study had discontinued initial IFX treatment
because of a lack of effectiveness; therefore, our data are
consistent with smaller scale studies that showed that
patients who discontinue IFX can respond effectively to
subsequent ETN treatment [15–21, 27]. In contrast to a
study demonstrating that patients switching from ETN to
IFX required higher doses of IFX when compared with
ETN-naive patients [13], IFX-treated patients in the present
study did not require higher doses of ETN to achieve
responses compared to IFX-naive patients.
Overall, treatment continuation was good in both
groups, regardless of previous IFX experience, and was at
least as good as continuation rates observed in other IFX-
to-ETN switching studies [20, 27, 28]. Regardless of prior
treatment history, most patients continued to receive ETN
for the duration of the study. Pre-IFX patients had a slightly
higher rate of continuation throughout the study and sig-
niﬁcantly higher participation at the end of the treatment
period compared with non-IFX patients. Signiﬁcantly,
fewer pre-IFX patients experienced AEs that led to
100
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Against Rheumatism responses.
IFX inﬂiximab. *P\0.05
versus week 4 for good
responders (Fisher’s exact test)
Table 3 Differences between ETN and IFX
Difference in mode of action ETN IFX
MTX effects on pharmacokinetics [25] None Increase in serum concentration
Speciﬁcity [26] TNF alpha/LT alpha TNF alpha
Transmembrane TNF binding/neutralization [26] ?? ???
Half-life, days [25] 4.8 9.5
In vitro complement activation [25] No Yes
Structure [26]H u
sTNFR2-Fccl
Mo/Hu chimeric
IgGj
Neutralizing antibody [24] No Yes
Reverse signaling [26]
Apoptosis [26] ± ???
Cytokine suppression [26] ± ???
Peak-trough ratios [26] Low High
± very weak; ?? moderate; ??? strong
ETN etanercept; Fc fusion; Hu human; IFX inﬂiximab; IgG immunoglobulin G; LT lymphotoxin; Mo murine; MTX methotrexate; TNF tumor
necrosis factor; sTNFR2 soluble TNF receptor 2
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123discontinuation compared with IFX-naive patients. Gen-
erally, pre-IFX patients were younger and healthier (fewer
comorbidities) compared with IFX-naive patients, which
may contribute to the lower rate of ETN discontinuation
observed in the pre-IFX group.
The most common AE reported among all patients
during the study was non-serious infection. There were no
signiﬁcant differences in the types of AEs reported by
pre- and non-IFX patients, suggesting that the safety
proﬁle of ETN is not changed by previous IFX experi-
ence. Overall, the incidence of AEs and SAEs was lower
among patients with previous IFX exposure, which is
encouraging given that a proportion of these patients
discontinued previous IFX treatment because of AEs
related to IFX.
Many RA treatment regimens that use biologic
DMARDs also incorporate MTX, and the tolerability of
multidrug treatment regimens is a common concern.
Although MTX is not consistently used in ETN regimens,
MTX is usually administered with IFX because MTX
inhibits the production of human antichimeric antibodies,
which can interfere with treatment effectiveness and induce
autoimmune sequelae [29, 30]. MTX is currently approved
as a second-line agent in Japan, and the recommended dose
is lower (upper limit is 8 mg/wk) than that in the European
Union or the United States, owing to the higher incidence
of AEs observed among Japanese patients in MTX clinical
trials [31]. In this study, the concomitant use of MTX and
ETN did not cause an increase in SAEs in pre- or non-IFX
patients compared with patients receiving ETN mono-
therapy, suggesting that MTX use is not a major factor in
predicting SAEs in these patients. It should be noted that
more pre-IFX patients received concomitant MTX therapy
compared with non-IFX patients. Although the reasons for
increased tolerability to the combination of ETN and MTX
are not clear, pre-IFX patients tended to be younger, had a
shorter duration of RA, and had fewer comorbidities when
compared with non-IFX patients. These data imply that
patients healthy enough to be treated with MTX may have
a lower incidence of SAEs resulting from combination
therapy.
The present study is limited, in part, by its observational
nature. Patients were followed for only up to 6 months, and
radiographic analysis was not performed to conﬁrm
effectiveness. In addition, the period of IFX treatment and
the period between the ﬁnal infusion of IFX and the ﬁrst
injection of ETN were conﬁrmed only for a subset of
patients. This study does not deﬁnitively demonstrate
whether ETN treatment is effective for all patients with RA
who are non-responsive to IFX, nor does it address the
issue of recurrence of AEs in patients who switched from
IFX treatment because of AEs. In addition, differences in
baseline patient demographics with regard to age, disease
onset and duration, background DMARD therapy, and
comorbidities may have affected the results.
The interim analysis of this large observational registry
study demonstrated, in a real-world setting, the safety and
effectiveness of ETN treatment in patients with active RA
who were switched from previous IFX treatment as a result
of lack of effectiveness or AEs. ETN treatment was
effective and well tolerated in both pre-IFX and non-IFX
patients. Overall, patients with prior IFX experience had
safety and effectiveness outcomes that were as good as
those of patients who were naive to IFX treatment.
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